Showing 4281-4290 of 9153 results for "".
- Method Review: A Closer Look at Cryo-EM’s Impact on Dermatologyhttps://practicaldermatology.com/news/method-review-a-closer-look-at-cryo-ems-impact-on-dermatology/2470806/A recent method review in the Journal of Investigative Dermatology points to the potential of cryogenic electron microscopy (cryo-EM) in dermatological research. According to the authors, advanced imaging technology enables atomic-resolution visualization of macromolecules in thei
- Castle Biosciences' Test Identifies AD Patients Likely to Achieve EASI90https://practicaldermatology.com/news/castle-biosciences-test-identifies-ad-patients-likely-achieve-easi90/2470795/Castle Biosciences has announced its investigational gene expression profile test for atopic dermatitis (AD) may identify patients likely to achieve a 90% or greater reduction in Eczema Area and Severity Index (EASI) scores within three months of targeted therapy initiation. Currently, ov
- New Computational System Evaluates Vitiligo Repigmentation Rateshttps://practicaldermatology.com/news/new-computational-system-evaluates-vitiligo-repigmentation-rates/2470766/A research team from Shenzhen People’s Hospital have developed a computational system for evaluating repigmentation rates in vitiligo patients, according to a new paper in the Journal of Investigative Dermatology. The retrospective study, conducted from June 2019 to November 2022
- Extended Analysis Confirms Favorable Safety for Upadacitinibhttps://practicaldermatology.com/news/extended-analysis-confirms-favorable-safety-upadacitinib/2470761/Results from a long-term integrated analysis support the favorable safety profile of upadacitinib for moderate-to-severe atopic dermatitis (AD) in adolescents and adults. The analysis, presented at the recent Revolutionizing Atopic Dermatitis (RAD) Conference, included over 9,000 patient-y
- Arcutis Submits sNDA for Roflumilast for Children 2 to 5 With ADhttps://practicaldermatology.com/news/arcutis-submits-snda-roflumilast-children-2-5-ad/2470667/Arcutis Biotherapeutics, Inc. announced the submission of a supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA) for roflumilast (ZORYVE) cream 0.05%, a once-daily, next-generation phosphodiesterase 4 (PDE4) inhibitor, for the topical treatment of mild-to-moderate
- FDA Approves Tapinarof Cream, 1%, for ADhttps://practicaldermatology.com/news/fda-approves-tapinarof-cream-1-ad/2470664/The US Food and Drug Administration (FDA) approved tapinarof cream, 1%, an aryl hydrocarbon receptor agonist, for an additional indication of the topical treatment of atopic dermatitis (AD) in adults and pediatric patients 2 years of age and older, Organon announced. Organon received the FDA appr
- JAK Inhibitors May Help Eosinophilic Colitis in AD Patientshttps://practicaldermatology.com/news/jak-inhibitors-may-help-eosinophilic-colitis-ad-patients/2468766/Janus kinase (JAK) inhibitors show promise in managing eosinophilic colitis (EoC) in adults with coexisting atopic dermatitis (AD), according to results from a novel case series. Researchers publishing in The Clinical Journal of Gastroenterology presented four cases of adult EoC s
- Veradermics Gets New Financing for AGA/PHL Candidatehttps://practicaldermatology.com/news/veradermics-gets-new-financing-agaphl-candidate/2468761/Veradermics announced the closing of a $75 million Series B financing, proceeds of which will be used to fund the ongoing clinical development of the company’s lead candidate VDPHL01 for the treatment of androgenetic alopecia (AGA), or pattern hair loss (PHL). "The initiation of our pivota
- Melasma Clinical Trials Show Advancements in Inclusive Representationhttps://practicaldermatology.com/news/melasma-clinical-trials-show-advancements-inclusive-representation/2468760/A new analysis of melasma clinical trials indicates progress toward inclusivity, with broad gender, racial, and Fitzpatrick skin type (FST) representation. Researchers publishing in the Journal of Drugs in Dermatology analyzed melasma clinical trials listed on ClinicalTrials.gov,
- FDA Clears Illuminate PRP System for Clinical Usehttps://practicaldermatology.com/news/fda-clears-illuminate-prp-system-clinical-use/2468757/Illuminate PRP’s platelet-rich plasma (PRP) system has received FDA clearance for clinical use, the company announced. The FDA-cleared single-spin PRP system offers a fast, efficient method for preparing high-quality PRP with high platelet capture rates, providing physicians with a reliabl